Creating Innovative Medicines and New Horizons in Healthcare

07 Jun , 12:00–13:15
Technologies Shaping the Future
Pavilion G, conference hall G7

A couple of hundred years ago, pneumonia and appendicitis were a fatal diagnosis and surgeons had no idea about the need to wash their hands before surgery. Medicine is moving forward alongside technological progress. Infectious disease epidemics are becoming a thing of the past, giving way to new, previously unknown diseases, for which neither treatment nor their consequences are yet fully understood. Today, advanced technologies not only allow for unique surgeries and diseases prevention, but also new treatments. One of the goals of the National Medicines Policy 2030 is to develop domestic innovative medicines. The development of a new medicine – from the idea to implementation – takes more than ten years and requires huge investments with high risks. Biomedical cell products (BMCP) have become a new driver for the global medicine market. Russia has already undertaken vast research and development in this field that might allow it to overtake the U.S. and the EU in terms of BMCP output over the next few decades. What are Russia’s priorities for developing new medicines? Which agency should manage the programme for the development of innovative medicines? What measures of state support and stimulus of commercialization are needed for the BMCP industry and the creation of innovative medicines? How attractive are investments in biomedical cell technologies? Will cell products become the ‘magic pill’ to combat 21st century diseases?

Alexey Martynov, President, Association of Biomedical Cellular Products Manufacturers

Andrei Belousov, Aide to the President of the Russian Federation
Max Wegner, Senior Vice President, Head of Regulatory Affairs, Pharmaceuticals Division, Bayer AG
Sergei Lukyanov, Rector, Pirogov Russian National Research Medical University
Dmitry Morozov, General Director, BIOCAD
Mikhail Murashko, Head, Federal Service on Surveillance in Healthcare (Roszdravnadzor)
Alexey Repik, Chairman, Russian-Japanese Business Council; President, Delovaya Rossiya (Business Russia); Chairman of the Board, Group R-Pharm
Veronika Skvortsova, Minister of Health of the Russian Federation
Guzel Ulumbekova, Head, Higher School of Healthcare Organization and Management
Yoshikazu Hayashi, Senior Executive Director, Pharmaceuticals and Medical Devices Agency
Sergey Tsyb, First Deputy Minister of Industry and Trade of the Russian Federation

Front row participants
Alexey Belyaev, Director, National Medical Research Center of Oncology named after N.N. Petrov of the Ministry of Health of the Russian Federation
Andrey Vasiliev, Director, Koltzov Institute of Developmental Biology of Russian Academy of Sciences
Petr Glybochko, Rector, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Dmitry Kudlay, General Director, Generium
Vadim Merkulov, Deputy Director General for Drug Expertise, Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation
Gennady Suhih, Director, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Health of the Russian Federation